Science and Research
RUBY: A Study to Evaluate the Clinical Safety and Efficacy of OKG-0301 in the Treatment of Acute Adenoviral Conjunctivitis
Overview
The RUBY trial is a phase II, multi-centre, randomised, double masked, placebo-controlled, clinical trial of the study drug OKG-0301 in adenoviral conjunctivitis patients.
The purpose of the research is to test if the OKG-0301 can reduce the length of time patients are infectious with adenoviral conjunctivitis, as well as reducing common signs and symptoms such as eye redness and eye discharge.
This is a short study where patients will be followed up for 4 visits over 14 days. Patients on the study will be randomised into one of three treatment groups: placebo (no medical benefit), OKG-0301 in 0.03% strength or OKG-0301 in 0.012% strength.
- Principal Investigator
Professor Mark Daniell
The RUBY trial is a phase II, multi-centre, randomised, double masked, placebo-controlled, clinical trial of the study drug OKG-0301 in adenoviral conjunctivitis patients.
The purpose of the research is to test if the OKG-0301 can reduce the length of time patients are infectious with adenoviral conjunctivitis, as well as reducing common signs and symptoms such as eye redness and eye discharge.
This is a short study where patients will be followed up for 4 visits over 14 days. Patients on the study will be randomised into one of three treatment groups: placebo (no medical benefit), OKG-0301 in 0.03% strength or OKG-0301 in 0.012% strength.
- Principal Investigator
Learn more
View this study at ClinicalTrials.gov
This international database listing provides more detailed information about this study.